Blaze Bioscience, Inc.

Blaze Bioscience, Inc. develops innovative biotechnology solutions aimed at improving cancer treatment outcomes, focusing on advanced diagnostic and therapeutic technologies designed for enhanced surgical precision. Founded in 2010, Blaze Bioscience, Inc. is headquartered in Seattle, US, and specializes in cancer treatment solutions.

The company has successfully completed 6 funding deals, with its most recent funding round occurring on February 1, 2019, raising USD 5 mn. Jim Olson, the founder, has a background in developing medical technologies, contributing to the firm's strategic direction. Heather Franklin currently serves as the CEO. Blaze Bioscience, Inc.

specializes in biotechnology solutions aimed at enhancing cancer patient outcomes through innovative diagnostic and therapeutic technologies. The company's core offering, Tumor Paint®, is a proprietary technology designed to improve the visualization and surgical removal of tumors by utilizing a molecular imaging system. This product, in conjunction with the CANVAS® imaging system, enables surgeons to detect cancerous tissues with greater sensitivity and reliability, thereby facilitating more precise surgical interventions. The primary end users of these products include hospitals, surgical centers, and oncologists in various geographic markets, including the United States and Europe, where there is a significant demand for advanced cancer detection and treatment options.

Blaze Bioscience focuses on providing solutions that address the critical challenges of tumor identification and removal, thereby enhancing the overall treatment experience for patients. Blaze Bioscience operates on a business model that involves direct sales to healthcare institutions and partnerships with surgical centers, allowing them to integrate their Tumor Paint® and CANVAS® imaging systems into clinical workflows. Revenue generation occurs through product sales, including agreements for the provision of their flagship technologies to hospitals and surgery centers. Transactions may follow a structured pricing plan encompassing one-time purchases or subscription agreements for ongoing support and updates of the imaging systems.

This model positions Blaze Bioscience to capitalize on the growing demand for precision-based cancer treatments, with revenue streams linked directly to the adoption of their innovative technologies in medical practices. In February 2019, Blaze Bioscience, Inc. raised USD 5 mn in venture funding to support their growth initiatives. The company plans to expand its product offerings, including the development of enhanced versions of Tumor Paint® and the CANVAS® imaging system.

Additionally, Blaze Bioscience aims to enter new markets within Europe and Asia by 2025, targeting hospitals and surgical centers seeking improved cancer detection solutions. This funding will enable the company to accelerate product development and market entry strategies.